Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Change in Accured Expenses (2016 - 2026)

Akebia Therapeutics has reported Change in Accured Expenses over the past 10 years, most recently at $13.9 million for Q4 2025.

  • Quarterly Change in Accured Expenses rose 185.7% to $13.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $48.5 million through Dec 2025, up 479.82% year-over-year, with the annual reading at $48.5 million for FY2025, 479.82% up from the prior year.
  • Change in Accured Expenses was $13.9 million for Q4 2025 at Akebia Therapeutics, down from $15.8 million in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $30.8 million in Q3 2021 and troughed at -$37.2 million in Q4 2021.
  • The 5-year median for Change in Accured Expenses is $1.6 million (2024), against an average of -$1.7 million.
  • Year-over-year, Change in Accured Expenses crashed 440.04% in 2023 and then soared 2984.2% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at -$37.2 million in 2021, then skyrocketed by 55.7% to -$16.5 million in 2022, then surged by 122.55% to $3.7 million in 2023, then soared by 31.26% to $4.9 million in 2024, then skyrocketed by 185.7% to $13.9 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Change in Accured Expenses are $13.9 million (Q4 2025), $15.8 million (Q3 2025), and $16.0 million (Q2 2025).